Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas.

ABSTRACT: T-cell lymphomas are a heterogeneous group of cancers with different pathogenesis and poor prognosis. Histone deacetylases (HDACs) are epigenetic modifiers that modulate many key biological processes. In recent years, HDACs have been fully investigated for their roles and potential as drug targets in T-cell lymphomas. In this review, we have deciphered the modes of action of HDACs, HDAC inhibitors as single agents, and HDACs guided combination therapies in T-cell lymphomas. The overview of HDACs on the stage of T-cell lymphomas, and HDACs guided therapies both as single agents and combination regimens endow great opportunities for the cure of T-cell lymphomas.

SUBMITTER: Zhang Q 

PROVIDER: S-EPMC6428980 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature